07:34 AM EDT, 05/22/2024 (MT Newswires) -- Medicenna Therapeutics ( MDNAF ) , whose shares rose 4.4% yesterday, on Wednesday said it will present an update on the MDNA11 ABILITY-1 Trial at the 10th annual Sachs Oncology Innovation Forum on May 31.

The company will present updated data from its Phase 1/2 ABILITY-1 study including anti-tumor activity, safety, pharmacokinetic and pharmacodynamic data following treatment with MDNA11, which is being evaluated as both a monotherapy and in combination with pembrolizumab (Merck's Keytruda) in patients with advanced or metastatic solid tumors.

The Oncology Innovation Forum is part of the clinical partnering and investment activities surrounding the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 31-June 4.